Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2924MR)

This product GTTS-WQ2924MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2924MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6648MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ11882MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ10346MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ3122MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ13413MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ3574MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ12879MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ14934MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW